Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
about
ROR1, an embryonic protein with an emerging role in cancer biologyThe dual role of the novel Wnt receptor tyrosine kinase, ROR2, in human carcinogenesisThe role of Ryk and Ror receptor tyrosine kinases in Wnt signal transductionmicroRNA regulation of Wnt signaling pathways in development and diseaseThe pathogenesis of chronic lymphocytic leukemiaTherapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignanciesSilencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaWnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activityStat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.Ror receptor tyrosine kinases: orphans no more.A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.Targeting malignant B cells with an immunotoxin against ROR1ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent AdjuvantTargeting ROR1 identifies new treatment strategies in hematological cancers.Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cellsCrosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic LeukemiaWnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Antibody-based therapeutics for the treatment of human B cell malignanciesRNAi screen for rapid therapeutic target identification in leukemia patients.Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.
P2860
Q26828533-227C44D3-CE51-44B5-8303-7BB6A5DC47D5Q26829919-4F3A9B61-B1E8-4F24-95B2-B87E27288CB4Q26852972-404A6717-9486-497D-9B5E-0F176B67D42FQ27011654-E972390A-E4D9-4100-A23A-DB04D520C149Q27025715-8E8D0EC5-DC3B-4679-BDC9-919DC8DA47CAQ28478591-C1D47CCB-13AE-49E1-991B-6C24DA17C457Q28547292-3C9A8AF2-32CC-40F0-B070-253A489561D1Q30008736-8FD92490-7DE3-4A39-8FFC-40E40C76C459Q30315828-0BD3A3DC-9EB6-485B-9CBD-AE0B31AB6099Q33371167-C26D73DB-13B2-43D7-B54E-1D9213563743Q33649606-CBE9460C-AECD-4616-BC0F-5119A67E9DCEQ33780253-2490329E-D395-4280-9231-D6E550E831A7Q34158454-7A185B10-7DB4-4A75-A88A-0939B33BB9A2Q34189274-86DA69E8-5750-4FF2-893F-36A1B84AAF43Q34374056-06716D29-D28A-4E5D-996E-666F8DEC489AQ34534333-C6B0BFE5-FE40-48C6-A189-D459CA78C422Q34747359-FCDE269F-2385-45B7-A9D3-E45015F35723Q34850710-F788F3A9-E508-47DD-9F36-6D7BF13712C0Q35029969-E069D228-C1A8-4D8E-95E3-F4568411C8CDQ35036351-7369D02F-2D73-4A0B-BF5C-1BDE03B7B210Q35071430-75F6852E-799D-481C-BD7D-4888FF87F94CQ35188629-4D91B945-AA3D-4E2E-A6CE-9EC696C1E590Q35648352-D5242159-7102-4285-9C0B-9A90609F91DAQ35690979-19B581CF-D1EE-464C-BB6E-816D52ED203BQ35839793-822B6FE0-FE83-4723-A368-43CF58D41FE4Q35969887-B8D92C4C-3436-4BE3-94CA-6DB782A549DFQ35971763-38A1EA9E-1D53-45A6-A773-5C796AFBD444Q36088818-F6A48E94-89C9-4D7C-BED6-1D5144F73171Q36346494-CFCEBB84-9645-439A-A411-573461EE2487Q36347760-3CDD046F-A875-4ECD-BB15-5982AE8B9A90Q36406203-06FFC921-F726-448E-8BAF-E4064F41E2EEQ36433018-CB984631-E78F-47DD-B5E6-8C36A4D689E4Q36471596-7E3B06C1-C525-4DF4-9347-09C3E8656BFEQ36515159-59928F22-CFDD-430C-863A-C0065E2131D6Q36799192-B63B173A-0EB5-418E-9F7D-77F3B5A71986Q36907540-4DB4891D-5975-42CD-84E6-A6844104502FQ37187716-89F572D9-47C0-43FE-B9A3-E3151892A2AEQ37244349-AC9F9945-8FB2-4437-B89C-AE7522FF18F2Q37320359-3BF02C9E-FD12-42A9-B979-DF27B4B5C1FFQ37405620-36FCE7D2-E226-4BAA-B769-B071018D2F93
P2860
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Unique cell surface expression ...... chronic lymphocytic leukemia.
@ast
Unique cell surface expression ...... chronic lymphocytic leukemia.
@en
Unique cell surface expression ...... chronic lymphocytic leukemia.
@nl
type
label
Unique cell surface expression ...... chronic lymphocytic leukemia.
@ast
Unique cell surface expression ...... chronic lymphocytic leukemia.
@en
Unique cell surface expression ...... chronic lymphocytic leukemia.
@nl
prefLabel
Unique cell surface expression ...... chronic lymphocytic leukemia.
@ast
Unique cell surface expression ...... chronic lymphocytic leukemia.
@en
Unique cell surface expression ...... chronic lymphocytic leukemia.
@nl
P2093
P1476
Unique cell surface expression ...... l chronic lymphocytic leukemia
@en
P2093
Adrian Wiestner
Elinor Lee
Jessica M Levy
Ka Yin Kwong
Louis M Staudt
Michael G Kennedy
Sivasubramanian Baskar
Thomas Hofer
Wyndham H Wilson
P304
P356
10.1158/1078-0432.CCR-07-1823
P407
P577
2008-01-01T00:00:00Z